Panelists discuss the emotional and diagnostic journey of a multiple myeloma patient and his care partner, highlighting how incidental back pain led to an unexpected cancer diagnosis, the initial ...

On July 2, the FDA approved linvoseltamab (Lynozyfic; Regeneron), a B-cell maturation antigen (BCMA) bispecific antibody, for the treatment of adults with relapsed or refractory multiple myeloma who ...

The FDA is reevaluating GlaxoSmithKline’s blood cancer drug Blenrep following mixed results from two phase 3 trials and mounting concerns about eye-related side effects and dosing. The agency is ...

Patients with (RRMM) and extramedullary disease (EMD) represent a particularly high-risk population with historically poor outcomes. In a new phase 2 analysis presented at the European Hematology ...

Panelists discuss the growing promise of GPRC5D-targeted therapy in relapsed/refractory multiple myeloma, highlighting MonumenTAL-1 trial data showing encouraging responses in heavily pretreated ...